Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ruff

Showing results (101-110 of 224) with videos related to

Pageof 23
Sort By:
Circulation|February 18, 2017
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic ValvesAnthony P Carnicelli, Raffaele De Caterina, Jonathan L Halperin, et al.
Plos One|April 11, 2022
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumabLaura E Korthauer, Robert P Giugliano, Jianping Guo, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 26, 2022
Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trialSiddharth M Patel, Michael G Palazzolo, Sabina A Murphy, et al.
International Journal of Cardiology|June 20, 2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Rose A Hamershock, et al.
Journal of the American College of Cardiology|September 10, 2016
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 AnalysisJan Steffel, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.
International Journal of Cardiology|May 21, 2023
Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trialAntonio Fagundes, Christian T Ruff, David A Morrow, et al.
Circulation|July 4, 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialOphelia Q P Yin, Elliott M Antman, Eugene Braunwald, et al.
JACC. Clinical Electrophysiology|April 26, 2023
Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure PhenotypesRiccardo M Inciardi, Robert P Giugliano, Jeong-Gun Park, et al.
Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.
Pageof 23

Showing results (101-110 of 224) with videos related to

Sort By:
Pageof 23
Circulation|February 18, 2017
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic ValvesAnthony P Carnicelli, Raffaele De Caterina, Jonathan L Halperin, et al.
Plos One|April 11, 2022
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumabLaura E Korthauer, Robert P Giugliano, Jianping Guo, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 26, 2022
Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trialSiddharth M Patel, Michael G Palazzolo, Sabina A Murphy, et al.
International Journal of Cardiology|June 20, 2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Rose A Hamershock, et al.
Journal of the American College of Cardiology|September 10, 2016
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 AnalysisJan Steffel, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.
International Journal of Cardiology|May 21, 2023
Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trialAntonio Fagundes, Christian T Ruff, David A Morrow, et al.
Circulation|July 4, 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialOphelia Q P Yin, Elliott M Antman, Eugene Braunwald, et al.
JACC. Clinical Electrophysiology|April 26, 2023
Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure PhenotypesRiccardo M Inciardi, Robert P Giugliano, Jeong-Gun Park, et al.
Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.
Pageof 23